Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777908 | 0.86 | ASIC1 (0.37) | KCNK3MAPTASIC1KMT2AKLK7 | |
| SCHEMBL19711705 | 0.85 | KCNK3 (0.40) | KCNK3MAPTASIC1KMT2AMEN1 | |
| SCHEMBL17777940 | 0.82 | KCNK3 (0.40) | KCNK3MAPTASIC1KMT2AKLK7 | |
| SCHEMBL17777930 | 0.82 | KCNK3 (0.38) | KCNK3MAPTASIC1KMT2AMEN1 | |
| SCHEMBL25632913 | 0.81 | KCNK3 (0.37) | KCNK3MAPTASIC1KMT2AMEN1 | |
| SCHEMBL17777764 | 0.80 | PTGDR2 (0.42) | MAPTKMT2AMEN1PTGDR2ALDH1A1 | |
| SCHEMBL21451580 | 0.79 | ASIC1 (0.37) | KCNK3MAPTASIC1KMT2AMEN1 | |
| SCHEMBL19702813 | 0.77 | PTGDR2 (0.41) | KMT2AKLK7MEN1PTGDR2LMNA | |
| SCHEMBL17777810 | 0.76 | ASIC1 (0.36) | KCNK3MAPTASIC1KMT2AMEN1 | |
| SCHEMBL19659387 | 0.71 | CYP2D6 (0.34) | MAPTKMT2AMEN1PTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183247-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20170355699-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2016081918-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355699-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | KCNK3 4151/4885MAPT 982/4885ASIC1 4848/4885 |
| US-20230183247-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | KCNK3 4151/4885MAPT 982/4885ASIC1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.